<i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
Non-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/15/12232 |
| _version_ | 1797586603725553664 |
|---|---|
| author | Florian Plaza Oñate Célia Chamignon Sebastian D. Burz Nicolas Lapaque Magali Monnoye Catherine Philippe Maxime Bredel Laurent Chêne William Farin Jean-Michel Paillarse Jérome Boursier Vlad Ratziu Pierre-Yves Mousset Joël Doré Philippe Gérard Hervé M. Blottière |
| author_facet | Florian Plaza Oñate Célia Chamignon Sebastian D. Burz Nicolas Lapaque Magali Monnoye Catherine Philippe Maxime Bredel Laurent Chêne William Farin Jean-Michel Paillarse Jérome Boursier Vlad Ratziu Pierre-Yves Mousset Joël Doré Philippe Gérard Hervé M. Blottière |
| author_sort | Florian Plaza Oñate |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through analyses of the gut microbiota with shotgun metagenomics, we observe that compared to healthy controls, <i>Adlercreutzia equolifaciens</i> is depleted in patients with liver diseases such as NAFLD. Its abundance also decreases as the disease progresses and eventually disappears in the last stages indicating a strong association with disease severity. Moreover, we show that <i>A. equolifaciens</i> possesses anti-inflammatory properties, both in vitro and in vivo in a humanized mouse model of NAFLD. Therefore, our results demonstrate a link between NAFLD and the severity of liver disease and the presence of <i>A. equolifaciens</i> and its anti-inflammatory actions. Counterbalancing dysbiosis with this bacterium may be a promising live biotherapeutic strategy for liver diseases. |
| first_indexed | 2024-03-11T00:25:27Z |
| format | Article |
| id | doaj.art-67167103342d49d98e50e5a9028c6ffe |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T00:25:27Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-67167103342d49d98e50e5a9028c6ffe2023-11-18T23:02:15ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-07-0124151223210.3390/ijms241512232<i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver DiseaseFlorian Plaza Oñate0Célia Chamignon1Sebastian D. Burz2Nicolas Lapaque3Magali Monnoye4Catherine Philippe5Maxime Bredel6Laurent Chêne7William Farin8Jean-Michel Paillarse9Jérome Boursier10Vlad Ratziu11Pierre-Yves Mousset12Joël Doré13Philippe Gérard14Hervé M. Blottière15Université Paris-Saclay, INRAE, MGP, MetaGenoPolis, 78350 Jouy-en-Josas, FranceNovoBiome, 33360 Latresne, FranceUniversité Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, FranceUniversité Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, FranceUniversité Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, FranceUniversité Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, FranceNovoBiome, 33360 Latresne, FranceEnterome, 75011 Paris, FranceEnterome, 75011 Paris, FranceEnterome, 75011 Paris, FranceUniversité d’Angers, SFR ICAT4208, Laboratoire HIFIH & Centre Hospitalier d’Angers, 49100 Angers, FranceSorbonne-Université, Hôpital Pitié-Salpêtrière, INSERM UMRS 1138, Centre de Recherche des Cordeliers, 75006 Paris, FranceNovoBiome, 33360 Latresne, FranceUniversité Paris-Saclay, INRAE, MGP, MetaGenoPolis, 78350 Jouy-en-Josas, FranceUniversité Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, 78350 Jouy-en-Josas, FranceUniversité Paris-Saclay, INRAE, MGP, MetaGenoPolis, 78350 Jouy-en-Josas, FranceNon-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through analyses of the gut microbiota with shotgun metagenomics, we observe that compared to healthy controls, <i>Adlercreutzia equolifaciens</i> is depleted in patients with liver diseases such as NAFLD. Its abundance also decreases as the disease progresses and eventually disappears in the last stages indicating a strong association with disease severity. Moreover, we show that <i>A. equolifaciens</i> possesses anti-inflammatory properties, both in vitro and in vivo in a humanized mouse model of NAFLD. Therefore, our results demonstrate a link between NAFLD and the severity of liver disease and the presence of <i>A. equolifaciens</i> and its anti-inflammatory actions. Counterbalancing dysbiosis with this bacterium may be a promising live biotherapeutic strategy for liver diseases.https://www.mdpi.com/1422-0067/24/15/12232NAFLDgut microbiotainflammationmetagenomicslive biotherapeutic product |
| spellingShingle | Florian Plaza Oñate Célia Chamignon Sebastian D. Burz Nicolas Lapaque Magali Monnoye Catherine Philippe Maxime Bredel Laurent Chêne William Farin Jean-Michel Paillarse Jérome Boursier Vlad Ratziu Pierre-Yves Mousset Joël Doré Philippe Gérard Hervé M. Blottière <i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease International Journal of Molecular Sciences NAFLD gut microbiota inflammation metagenomics live biotherapeutic product |
| title | <i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease |
| title_full | <i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease |
| title_fullStr | <i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease |
| title_full_unstemmed | <i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease |
| title_short | <i>Adlercreutzia equolifaciens</i> Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease |
| title_sort | i adlercreutzia equolifaciens i is an anti inflammatory commensal bacterium with decreased abundance in gut microbiota of patients with metabolic liver disease |
| topic | NAFLD gut microbiota inflammation metagenomics live biotherapeutic product |
| url | https://www.mdpi.com/1422-0067/24/15/12232 |
| work_keys_str_mv | AT florianplazaonate iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT celiachamignon iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT sebastiandburz iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT nicolaslapaque iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT magalimonnoye iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT catherinephilippe iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT maximebredel iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT laurentchene iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT williamfarin iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT jeanmichelpaillarse iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT jeromeboursier iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT vladratziu iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT pierreyvesmousset iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT joeldore iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT philippegerard iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease AT hervemblottiere iadlercreutziaequolifaciensiisanantiinflammatorycommensalbacteriumwithdecreasedabundanceingutmicrobiotaofpatientswithmetabolicliverdisease |